• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

    2/24/25 4:05:00 PM ET
    $HIMS
    Medical/Nursing Services
    Health Care
    Get the next $HIMS alert in real time by email

    Revenue of $1.5 billion, up 69% year-over-year in 2024

    Net income of $126 million; Adjusted EBITDA of $177 million in 2024

    Subscribers grew to 2.2 million, up 45% year-over-year in 2024

    Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million

    Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com.

    "2024 was a fantastic year at Hims and Hers as we continue to build a platform that leverages personalization and technology unlike any traditional healthcare system," said Andrew Dudum, co-founder and CEO. "Over 2 million subscribers now entrust Hims & Hers to aid them in their journey to better health - with thousands more joining daily. In the coming years, we expect to further transform how individuals can improve their health with more comprehensive treatments, technologies that normalize unlimited follow up support, and tools that can eventually be exported beyond Hims and Hers, enabling even more Americans to access this care. We believe an ongoing focus in these areas will allow every household in the country to access high quality, precision care that is convenient and affordable and expect 2025 will be another exciting step toward our vision of this next-generation of healthcare."

    Yemi Okupe, CFO, stated, "The success we are experiencing is a direct reflection of our improving ability to democratize access to high quality, personalized care across each of our specialties. Revenue excluding our GLP-1 offering increased 43% year-over-year to over $1.2 billion in 2024, meeting our previous 2025 revenue target a year early. Consolidated revenue increased 69% year-over-year to nearly $1.5 billion as our weight loss offering continues to offer an accelerant to these trends. We believe this signifies our platform's growing ability to enter new specialties and scale rapidly, further establishing confidence that we are building a set of core capabilities that can scale with tremendous efficiency. This evolution is positioning us to serve tens of millions of individuals over time while simultaneously progressing toward our long-term profitability targets."

    Key Business Metrics

    (In Thousands, Except for Monthly Online Revenue per Average Subscriber and AOV, Unaudited)

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2024

     

    2023

     

    % Change

     

    2024

     

    2023

     

    % Change

    Subscribers (end of period)

     

     

    2,229

     

     

    1,537

     

    45

    %

     

     

    2,229

     

     

    1,537

     

    45

    %

    Monthly Online Revenue per Average Subscriber

     

    $

    73

     

    $

    53

     

    38

    %

     

    $

    64

     

    $

    54

     

    19

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Net Orders

     

     

    2,807

     

     

    2,298

     

    22

    %

     

     

    10,459

     

     

    8,676

     

    21

    %

    AOV

     

    $

    168

     

    $

    103

     

    63

    %

     

    $

    137

     

    $

    97

     

    41

    %

    Revenue

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended

    December 31,

     

    Year Ended

    December 31,

     

     

    2024

     

    2023

     

    % Change

     

    2024

     

    2023

     

    % Change

    Online Revenue

     

    $

    470,760

     

    $

    237,363

     

    98

    %

     

    $

    1,437,937

     

    $

    842,381

     

    71

    %

    Wholesale Revenue

     

     

    10,379

     

     

    9,256

     

    12

    %

     

     

    38,577

     

     

    29,619

     

    30

    %

    Total revenue

     

    $

    481,139

     

    $

    246,619

     

    95

    %

     

    $

    1,476,514

     

    $

    872,000

     

    69

    %

    Fourth Quarter 2024 Financial Highlights

    • Revenue was $481.1 million for the fourth quarter of 2024 compared to $246.6 million for the fourth quarter of 2023, an increase of 95% year-over-year.
    • Gross margin was 77% for the fourth quarter of 2024 compared to 83% for the fourth quarter of 2023.
    • Net income was $26.0 million for the fourth quarter of 2024 compared to $1.2 million for the fourth quarter of 2023.
    • Adjusted EBITDA was $54.1 million for the fourth quarter of 2024 compared to $20.6 million for the fourth quarter of 2023.
    • Net cash provided by operating activities was $86.4 million for the fourth quarter of 2024 compared to $22.0 million for the fourth quarter of 2023.
    • Free Cash Flow was $59.5 million for the fourth quarter of 2024 compared to $10.8 million for the fourth quarter of 2023.

    Full Year 2024 Financial Highlights

    • Revenue was $1,476.5 million for the year ended December 31, 2024 compared to $872.0 million for the year ended December 31, 2023, an increase of 69% year-over-year.
    • Gross margin was 79% for the year ended December 31, 2024 compared to 82% for the year ended December 31, 2023.
    • Net income was $126.0 million for the year ended December 31, 2024, which was impacted by the change in valuation allowance of $68.0 million due to the full release of the valuation allowance on our domestic deferred tax assets. The benefit from the change in valuation allowance was partially offset by current period tax activity. This compared to a net loss of $(23.5) million for the year ended December 31, 2023.
    • Adjusted EBITDA was $176.9 million for the year ended December 31, 2024 compared to $49.5 million for the year ended December 31, 2023.
    • Net cash provided by operating activities was $251.1 million for the year ended December 31, 2024 compared to $73.5 million for the year ended December 31, 2023.
    • Free Cash Flow was $198.3 million for the year ended December 31, 2024 compared to $47.0 million for the year ended December 31, 2023.

    Reconciliations of Adjusted EBITDA and Free Cash Flow, non-GAAP measures, to net income (loss) and net cash provided by operating activities, respectively, their most comparable financial measures under generally accepted accounting principles in the United States ("U.S. GAAP"), have been provided in this press release in the accompanying tables. Additional information about Adjusted EBITDA and Free Cash Flow is also included below under the heading "Non-GAAP Financial Measures".

    Financial Outlook

    Hims & Hers is providing the following guidance:

    For the first quarter 2025, we expect:

    • Revenue of $520 million to $540 million.
    • Adjusted EBITDA of $55 million to $65 million, reflecting an Adjusted EBITDA margin of 11% to 12%.

    For the full year 2025, we expect:

    • Revenue of $2.3 billion to $2.4 billion.
    • Adjusted EBITDA of $270 million to $320 million, reflecting an Adjusted EBITDA margin of 12% to 13%.

    The guidance provided above constitutes forward-looking statements and actual results may differ materially. Refer to the "Cautionary Note Regarding Forward-Looking Statements" safe harbor section below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

    We have relied upon the exception in Item 10(e)(1)(i)(B) of Regulation S-K and have not reconciled forward-looking Adjusted EBITDA to its most directly comparable U.S. GAAP measure, net income (loss), because we cannot predict with reasonable certainty the ultimate outcome of certain components of such reconciliations, including market-related assumptions that are not within our control, or others that may arise, without unreasonable effort. For these reasons, we are unable to assess the probable significance of the unavailable information, which could materially impact the amount of future net income (loss). See "Non-GAAP Financial Measures" for additional important information regarding Adjusted EBITDA.

    Conference Call

    Hims & Hers will host a conference call to review the fourth quarter and full year 2024 results on February 24, 2025, at 5:00 p.m. ET. The conference call can be accessed by dialing +1 (888) 510-2630 for U.S. participants and +1 (646) 960-0137 for international participants, and referencing conference ID #1704296. A live audio webcast will be available online at investors.hims.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call at the same link.

    About Hims & Hers Health, Inc.

    Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health.

    We believe how you feel in your body and mind transforms how you show up in life. That's why we're building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalized care designed for results.

    For more information, please visit investors.hims.com.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believe," "estimate," "anticipate," "expect," "assume," "imply," "intend," "plan," "may," "will," "potential," "project," "predict," "continue," "could," "confident," "confidence," or "should," or, in each case, their plural, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, any statements relating to our financial outlook and guidance, including our mission to drive top-line growth and profitability and our ability to attain our medium- and long-term financial and operational targets; our expected future financial and business performance, including with respect to the Hims & Hers platform, our marketing campaigns, investments in innovation, the solutions accessible on our platform, and our infrastructure, and the underlying assumptions with respect to the foregoing; statements relating to events and trends relevant to us, including with respect to our regulatory environment, financial condition, results of operations, short- and long-term business operations, objectives, and financial needs; expectations regarding our mobile applications, market acceptance, user experience, customer retention, brand development, our ability to invest and generate a return on any such investment, customer acquisition costs, operating efficiencies and leverage (including our fulfillment capabilities), the effect of any pricing decisions, changes in our product or offering mix, the timing and market acceptance of any new products or offerings, the timing and anticipated effect of any pending or recently completed acquisitions, the success of our business model, our market opportunity, our ability to scale our business, the growth of certain of our specialties, our ability to innovate on and expand the scope of our offerings and experiences, including through the use of data analytics and artificial intelligence, our ability to reinvest into the customer experience, our ability to comply with the extensive, complex and evolving legal and regulatory requirements applicable to our business, including without limitation state and federal healthcare, privacy and consumer protection laws and regulations, and the effect or outcome of litigation or governmental actions in relation to any such legal and regulatory requirements. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

    The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Securities and Exchange Commission (the "Commission").

    Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. These risks and others described in the "Risk Factors" section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive.

    By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and developments in the industry in which we operate may differ materially from those made in or suggested by the forward-looking statements contained in reports we have filed or will file with the Commission, including our most recently filed Annual Report on Form 10-K, our most recently filed Quarterly Report on Form 10-Q, and any of our subsequent filings with the Commission. In addition, even if our results of operations, financial condition and liquidity, and developments in the industry in which we operate are consistent with the forward-looking statements contained in such reports, those results or developments may not be indicative of results or developments in subsequent periods.

    Key Business Metrics

    "Online Revenue" represents the sales of products and services on our platform, net of refunds, credits, and chargebacks, and includes revenue recognition adjustments recorded pursuant to U.S. GAAP, primarily relating to deferred revenue and returns reserve. Online Revenue is generated by selling directly to consumers through our websites and mobile applications. Our Online Revenue consists of products and services purchased by customers directly through our online platform. The majority of our Online Revenue is subscription-based, where customers agree to be billed on a recurring basis to have products and services automatically delivered to them.

    "Wholesale Revenue" represents non-prescription product sales to retailers through wholesale purchasing agreements. Wholesale Revenue also includes non-prescription product sales to third-party platforms through consignment arrangements. In addition to being revenue generative and profitable, wholesale partnerships and consignment arrangements have the added benefit of generating brand awareness with new customers in physical environments and on third-party platforms.

    "Subscribers" are customers who have one or more "Subscriptions" pursuant to which they have agreed to be automatically billed on a recurring basis at a defined cadence. The Subscription billing cadence is typically defined as a number of days (for example, billed every 30 days or every 90 days), which are excluded from our reporting when payment has not occurred at the contracted billing cadence. Subscribers can cancel or snooze Subscriptions in between billing periods to stop receiving additional products and/or services and can reactivate Subscriptions to continue receiving additional products and/or services.

    "Monthly Online Revenue per Average Subscriber" is defined as Online Revenue divided by "Average Subscribers", which amount is then further divided by the number of months in a period. "Average Subscribers" are calculated as the sum of the Subscribers at the beginning and end of a given period divided by 2.

    "Net Orders" are defined as the number of online customer orders minus transactions related to refunds, credits, chargebacks, and other negative adjustments. Net Orders represent transactions made on our platform during a defined period of time and exclude revenue recognition adjustments recorded pursuant to U.S. GAAP.

    Average Order Value ("AOV") is defined as Online Revenue divided by Net Orders.

     

    CONSOLIDATED BALANCE SHEETS

    (In Thousands, Except Share and Per Share Data)

     

     

    December 31,

     

     

    2024

     

     

     

    2023

     

    Assets

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    220,584

     

     

    $

    96,663

     

    Short-term investments

     

    79,667

     

     

     

    124,318

     

    Inventory

     

    64,427

     

     

     

    22,464

     

    Prepaid expenses and other current assets

     

    31,153

     

     

     

    21,608

     

    Total current assets

     

    395,831

     

     

     

    265,053

     

    Restricted cash

     

    856

     

     

     

    856

     

    Goodwill

     

    112,728

     

     

     

    110,881

     

    Property, equipment, and software, net

     

    82,083

     

     

     

    36,143

     

    Intangible assets, net

     

    43,410

     

     

     

    18,574

     

    Operating lease right-of-use assets

     

    10,881

     

     

     

    9,588

     

    Deferred tax assets, net

     

    61,603

     

     

     

    —

     

    Other long-term assets

     

    147

     

     

     

    91

     

    Total assets

    $

    707,539

     

     

    $

    441,186

     

    Liabilities and stockholders' equity

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    91,180

     

     

    $

    43,070

     

    Accrued liabilities

     

    53,013

     

     

     

    28,972

     

    Deferred revenue

     

    75,285

     

     

     

    7,733

     

    Earn-out payable

     

    —

     

     

     

    7,412

     

    Operating lease liabilities

     

    1,889

     

     

     

    1,281

     

    Total current liabilities

     

    221,367

     

     

     

    88,468

     

    Operating lease liabilities

     

    9,456

     

     

     

    8,667

     

    Other long-term liabilities

     

    —

     

     

     

    22

     

    Total liabilities

     

    230,823

     

     

     

    97,157

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock – Class A shares, par value $0.0001, 2,750,000,000 shares authorized and 212,459,586 and 205,104,120 shares issued and outstanding as of December 31, 2024 and 2023, respectively; Class V shares, par value $0.0001, 10,000,000 shares authorized and 8,377,623 shares issued and outstanding as of December 31, 2024 and 2023

     

    22

     

     

     

    21

     

    Additional paid-in capital

     

    719,155

     

     

     

    712,307

     

    Accumulated other comprehensive loss

     

    (324

    )

     

     

    (124

    )

    Accumulated deficit

     

    (242,137

    )

     

     

    (368,175

    )

    Total stockholders' equity

     

    476,716

     

     

     

    344,029

     

    Total liabilities and stockholders' equity

    $

    707,539

     

     

    $

    441,186

     

     

    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

    (In Thousands, Except Share and Per Share Data)

     

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Revenue

     

    $

    481,139

     

     

    $

    246,619

     

     

    $

    1,476,514

     

     

    $

    872,000

     

    Cost of revenue

     

     

    111,598

     

     

     

    42,561

     

     

     

    303,379

     

     

     

    157,051

     

    Gross profit

     

     

    369,541

     

     

     

    204,058

     

     

     

    1,173,135

     

     

     

    714,949

     

    Gross margin %

     

     

    77

    %

     

     

    83

    %

     

     

    79

    %

     

     

    82

    %

    Operating expenses:(1)

     

     

     

     

     

     

     

     

    Marketing

     

     

    221,085

     

     

     

    125,895

     

     

     

    678,844

     

     

     

    446,435

     

    Operations and support

     

     

    58,083

     

     

     

    32,839

     

     

     

    185,802

     

     

     

    119,857

     

    Technology and development

     

     

    23,749

     

     

     

    13,405

     

     

     

    78,819

     

     

     

    48,227

     

    General and administrative

     

     

    48,028

     

     

     

    32,319

     

     

     

    167,767

     

     

     

    129,883

     

    Total operating expenses

     

     

    350,945

     

     

     

    204,458

     

     

     

    1,111,232

     

     

     

    744,402

     

    Income (loss) from operations

     

     

    18,596

     

     

     

    (400

    )

     

     

    61,903

     

     

     

    (29,453

    )

    Other income (expense):

     

     

     

     

     

     

     

     

    Change in fair value of liabilities

     

     

    —

     

     

     

    (19

    )

     

     

    —

     

     

     

    (1,075

    )

    Other income, net

     

     

    3,695

     

     

     

    2,615

     

     

     

    9,808

     

     

     

    8,957

     

    Total other income, net

     

     

    3,695

     

     

     

    2,596

     

     

     

    9,808

     

     

     

    7,882

     

    Income (loss) before taxes

     

     

    22,291

     

     

     

    2,196

     

     

     

    71,711

     

     

     

    (21,571

    )

    Benefit (provision) for income taxes

     

     

    3,734

     

     

     

    (951

    )

     

     

    54,327

     

     

     

    (1,975

    )

    Net income (loss)

     

     

    26,025

     

     

     

    1,245

     

     

     

    126,038

     

     

     

    (23,546

    )

    Other comprehensive (loss) income

     

     

    (553

    )

     

     

    9

     

     

     

    (200

    )

     

     

    153

     

    Total comprehensive income (loss)

     

    $

    25,472

     

     

    $

    1,254

     

     

    $

    125,838

     

     

    $

    (23,393

    )

     

     

     

     

     

     

     

     

     

    Net income (loss) per share attributable to common stockholders:

     

     

     

     

     

     

     

     

    Basic

     

    $

    0.12

     

     

    $

    0.01

     

     

    $

    0.58

     

     

    $

    (0.11

    )

    Diluted

     

    $

    0.11

     

     

    $

    0.01

     

     

    $

    0.53

     

     

    $

    (0.11

    )

    Weighted average shares outstanding:

     

     

     

     

     

     

     

     

    Basic

     

     

    219,027,485

     

     

     

    211,584,915

     

     

     

    215,939,037

     

     

     

    209,344,712

     

    Diluted

     

     

    240,725,350

     

     

     

    221,850,856

     

     

     

    236,808,876

     

     

     

    209,344,712

     

     

    ______________

    (1) Includes stock-based compensation expense as follows (in thousands):

     

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2024

     

    2023

     

    2024

     

    2023

    Marketing

     

    $

    2,637

     

    $

    1,559

     

    $

    9,392

     

    $

    5,477

    Operations and support

     

     

    2,743

     

     

    1,920

     

     

    10,205

     

     

    6,815

    Technology and development

     

     

    3,824

     

     

    1,921

     

     

    12,534

     

     

    7,126

    General and administrative

     

     

    15,145

     

     

    12,391

     

     

    60,191

     

     

    46,662

    Total stock-based compensation expense

     

    $

    24,349

     

    $

    17,791

     

    $

    92,322

     

    $

    66,080

     

    CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In Thousands)

     

     

    Years Ended December 31,

     

     

    2024

     

     

     

    2023

     

    Operating activities

     

     

     

    Net income (loss)

    $

    126,038

     

     

    $

    (23,546

    )

    Adjustments to reconcile net income (loss) to net cash provided by operating activities

     

     

     

    Depreciation and amortization

     

    17,088

     

     

     

    9,515

     

    Stock-based compensation

     

    92,322

     

     

     

    66,080

     

    Change in fair value of liabilities

     

    —

     

     

     

    1,075

     

    Net accretion on securities

     

    (4,355

    )

     

     

    (5,686

    )

    Benefit for deferred taxes

     

    (61,649

    )

     

     

    (13

    )

    Impairment of long-lived assets

     

    114

     

     

     

    429

     

    Non-cash operating lease cost

     

    2,546

     

     

     

    1,922

     

    Non-cash acquisition-related costs

     

    —

     

     

     

    2,691

     

    Non-cash other

     

    357

     

     

     

    195

     

    Changes in operating assets and liabilities:

     

     

     

    Inventory

     

    (41,612

    )

     

     

    (902

    )

    Prepaid expenses and other current assets

     

    (9,494

    )

     

     

    (6,395

    )

    Other long-term assets

     

    (56

    )

     

     

    (58

    )

    Accounts payable

     

    43,710

     

     

     

    7,324

     

    Accrued liabilities

     

    23,791

     

     

     

    16,524

     

    Deferred revenue

     

    67,552

     

     

     

    6,261

     

    Operating lease liabilities

     

    (2,443

    )

     

     

    (1,933

    )

    Earn-out payable

     

    (2,825

    )

     

     

    —

     

    Net cash provided by operating activities

     

    251,084

     

     

     

    73,483

     

    Investing activities

     

     

     

    Purchases of investments

     

    (160,564

    )

     

     

    (157,239

    )

    Maturities of investments

     

    208,940

     

     

     

    170,051

     

    Proceeds from sales of investments

     

    725

     

     

     

    1,574

     

    Investment in website development and internal-use software

     

    (11,095

    )

     

     

    (9,272

    )

    Purchases of property, equipment, and intangible assets

     

    (41,655

    )

     

     

    (17,220

    )

    Acquisition of business, net of cash acquired

     

    (15,399

    )

     

     

    —

     

    Net cash used in investing activities

     

    (19,048

    )

     

     

    (12,106

    )

    Financing activities

     

     

     

    Proceeds from exercise of vested stock options

     

    26,651

     

     

     

    2,322

     

    Payments for taxes related to net share settlement of equity awards

     

    (52,501

    )

     

     

    (14,096

    )

    Repurchases of common stock

     

    (83,039

    )

     

     

    (1,999

    )

    Payments for acquisition-related earn-out consideration

     

    (3,190

    )

     

     

    —

     

    Proceeds from employee stock purchase plan

     

    3,901

     

     

     

    2,298

     

    Proceeds from exercise of Class A common stock warrants

     

    333

     

     

     

    —

     

    Net cash used in financing activities

     

    (107,845

    )

     

     

    (11,475

    )

    Foreign currency effect on cash and cash equivalents

     

    (270

    )

     

     

    (11

    )

    Increase in cash, cash equivalents, and restricted cash

     

    123,921

     

     

     

    49,891

     

    Cash, cash equivalents, and restricted cash at beginning of period

     

    97,519

     

     

     

    47,628

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    221,440

     

     

    $

    97,519

     

    Reconciliation of cash, cash equivalents, and restricted cash

     

     

     

    Cash and cash equivalents

    $

    220,584

     

     

    $

    96,663

     

    Restricted cash

     

    856

     

     

     

    856

     

    Total cash, cash equivalents, and restricted cash

    $

    221,440

     

     

    $

    97,519

     

    Supplemental disclosures of cash flow information

     

     

     

    Cash paid for taxes

    $

    7,916

     

     

    $

    1,109

     

    Non-cash investing and financing activities

     

     

     

    Purchases of property and equipment included in accounts payable and accrued liabilities

    $

    7,781

     

     

    $

    3,383

     

    Right-of-use asset obtained in exchange for lease liability

     

    2,593

     

     

     

    6,270

     

    Issuance of common stock for acquisition-related earn-out consideration

     

    1,396

     

     

     

    —

     

    Issuance of common stock and liabilities assumed in connection with acquisition of business

     

    16,000

     

     

     

    —

     

     

    Non-GAAP Financial Measures

    In addition to our financial results determined in accordance with U.S. GAAP, we present Adjusted EBITDA (which is a non-GAAP financial measure), Adjusted EBITDA margin (which is a non-GAAP ratio), and Free Cash Flow (which is a non-GAAP financial measure) each as defined below. We use Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, when taken together with the corresponding U.S. GAAP financial measures, provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. We consider Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that the use of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow is helpful to our investors as they are used by management in assessing the health of our business, our operating performance, and our liquidity.

    However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures or ratios differently or may use other financial measures or ratios to evaluate their performance, all of which could reduce the usefulness of Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow as tools for comparison. Reconciliations are provided below to the most directly comparable financial measures stated in accordance with U.S. GAAP. Investors are encouraged to review our U.S. GAAP financial measures and not to rely on any single financial measure to evaluate our business.

    Adjusted EBITDA is a key performance measure that our management uses to assess our operating performance. Because Adjusted EBITDA facilitates internal comparisons of our historical operating performance on a more consistent basis, we use this measure for business planning purposes. "Adjusted EBITDA" is defined as net income (loss) before stock-based compensation, depreciation and amortization, acquisition and transaction-related costs (which includes (i) consideration paid for employee compensation with vesting requirements incurred directly as a result of acquisitions, inclusive of revaluation of earn-out consideration recorded in general and administrative expenses prior to 2024, and (ii) transaction professional services), legal settlement expenses that are considered non-recurring, impairment of long-lived assets, change in fair value of liabilities, interest income, and income taxes. "Adjusted EBITDA margin" is defined as Adjusted EBITDA divided by revenue.

    Some of the limitations of Adjusted EBITDA include (i) Adjusted EBITDA does not properly reflect capital commitments to be paid in the future, and (ii) although depreciation and amortization are non-cash charges, the underlying assets may need to be replaced and Adjusted EBITDA does not reflect these capital expenditures. In evaluating Adjusted EBITDA, you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non-recurring items. We compensate for these limitations by providing specific information regarding the U.S. GAAP items excluded from Adjusted EBITDA. When evaluating our performance, you should consider Adjusted EBITDA in addition to, and not as a substitute for, other financial performance measures, including our net income (loss) and other U.S. GAAP results.

    Net Income (Loss) to Adjusted EBITDA Reconciliation

    (In Thousands, Unaudited)

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

     

     

     

     

     

     

     

     

    Revenue

    $

    481,139

     

     

    $

    246,619

     

     

    $

    1,476,514

     

     

    $

    872,000

     

     

     

     

     

     

     

     

     

    Net income (loss)

     

    26,025

     

     

     

    1,245

     

     

     

    126,038

     

     

     

    (23,546

    )

    Stock-based compensation

     

    24,349

     

     

     

    17,791

     

     

     

    92,322

     

     

     

    66,080

     

    Depreciation and amortization

     

    6,061

     

     

     

    2,658

     

     

     

    17,088

     

     

     

    9,515

     

    Acquisition and transaction-related costs

     

    2,155

     

     

     

    507

     

     

     

    3,979

     

     

     

    3,016

     

    Legal settlement

     

    2,008

     

     

     

    —

     

     

     

    2,008

     

     

     

    —

     

    Impairment of long-lived assets

     

    —

     

     

     

    —

     

     

     

    114

     

     

     

    429

     

    Change in fair value of liabilities

     

    —

     

     

     

    19

     

     

     

    —

     

     

     

    1,075

     

    Interest income

     

    (2,741

    )

     

     

    (2,601

    )

     

     

    (10,349

    )

     

     

    (9,029

    )

    (Benefit) provision for income taxes

     

    (3,734

    )

     

     

    951

     

     

     

    (54,327

    )

     

     

    1,975

     

    Adjusted EBITDA

    $

    54,123

     

     

    $

    20,570

     

     

    $

    176,873

     

     

    $

    49,515

     

     

     

     

     

     

     

     

     

    Net income (loss) as a % of revenue

     

    5

    %

     

     

    1

    %

     

     

    9

    %

     

     

    (3

    )%

    Adjusted EBITDA margin

     

    11

    %

     

     

    8

    %

     

     

    12

    %

     

     

    6

    %

     

    Free Cash Flow is a key performance measure that our management uses to assess our liquidity. Because Free Cash Flow facilitates internal comparisons of our historical liquidity on a more consistent basis, we use this measure for business planning purposes. "Free Cash Flow" is defined as net cash provided by operating activities, less purchases of property, equipment, and intangible assets and investment in website development and internal-use software in investing activities.

    Some of the limitations of Free Cash Flow include (i) Free Cash Flow does not represent our residual cash flow for discretionary expenditures and our non-discretionary commitments, and (ii) Free Cash Flow includes capital expenditures, the benefits of which may be realized in periods subsequent to those in which the expenditures took place. In evaluating Free Cash Flow, you should be aware that in the future we will have cash outflows similar to the adjustments in this presentation. Our presentation of Free Cash Flow should not be construed as an inference that our future results will be unaffected by these cash outflows or any unusual or non-recurring items. When evaluating our performance, you should consider Free Cash Flow in addition to, and not as a substitute for, other financial performance measures, including our net cash provided by operating activities and other U.S. GAAP results.

    Net Cash Provided By Operating Activities to Free Cash Flow Reconciliation

    (In Thousands, Unaudited)

     

     

     

    Three Months Ended December 31,

     

    Year Ended December 31,

     

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net cash provided by operating activities

     

    $

    86,385

     

     

    $

    21,983

     

     

    $

    251,084

     

     

    $

    73,483

     

    Less: purchases of property, equipment, and intangible assets in investing activities

     

     

    (24,520

    )

     

     

    (8,631

    )

     

     

    (41,655

    )

     

     

    (17,220

    )

    Less: investment in website development and internal-use software in investing activities

     

     

    (2,365

    )

     

     

    (2,567

    )

     

     

    (11,095

    )

     

     

    (9,272

    )

    Free Cash Flow

     

    $

    59,500

     

     

    $

    10,785

     

     

    $

    198,334

     

     

    $

    46,991

     

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250224659899/en/

    Investor Relations

    Bill Newby

    [email protected]

    Media Relations

    Abby Reisinger

    [email protected]

    Get the next $HIMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HIMS

    DatePrice TargetRatingAnalyst
    4/29/2025$30.00Buy → Hold
    TD Cowen
    2/18/2025$42.00 → $60.00Overweight → Equal-Weight
    Morgan Stanley
    1/10/2025$24.00 → $25.00Neutral → Sell
    Citigroup
    1/7/2025$35.00Buy
    BTIG Research
    12/17/2024$42.00Overweight
    Morgan Stanley
    11/14/2024Buy → Underperform
    BofA Securities
    8/22/2024$24.00Buy
    Needham
    8/9/2024Outperform → In-line
    Imperial Capital
    More analyst ratings

    $HIMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering size was increased

      5/8/25 10:25:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

      Proceeds intended to support Hims & Hers' global expansion through organic growth and strategic acquisitions, while also fueling deeper investment in AI, diagnostics, and personalized treatments to scale access and meet rising demand for high-quality, personalized care Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Him

      5/8/25 7:57:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    SEC Filings

    See more
    • Hims & Hers Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/13/25 5:23:44 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health Inc. filed SEC Form 8-K: Other Events

      8-K - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/9/25 7:00:17 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • SEC Form 10-Q filed by Hims & Hers Health Inc.

      10-Q - Hims & Hers Health, Inc. (0001773751) (Filer)

      5/5/25 4:17:34 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/12/24 3:52:47 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 1:33:02 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Hims & Hers Health Inc.

      SC 13G/A - Hims & Hers Health, Inc. (0001773751) (Subject)

      11/4/24 12:09:24 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

      Mo Elshenawy joins as the company doubles down on the role AI will play in the next generation of healthcare. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company's new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply personalized, accessible care at scale. This press release features multimedia. View the full release here: https://www.businesswire

      5/8/25 6:50:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Appoints Global Operations Expert and Amazon Veteran as Chief Operations Officer

      Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Nader Kabbani as Chief Operations Officer.1 A seasoned executive known for scaling trusted consumer and healthcare logistics businesses, Kabbani will oversee operations as the company expands access to personalized care for millions more individuals. This press release features multimedia. View the full release here: https://www.businesswire.com/ne

      5/5/25 9:01:00 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Define Ventures Appoints Carolyn Magill as Venture Partner

      The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

      3/11/25 5:30:00 AM ET
      $EVH
      $HIMS
      $LVGO
      Other Consumer Services
      Consumer Discretionary
      Medical/Nursing Services
      Health Care

    $HIMS
    Financials

    Live finance-specific insights

    See more

    $HIMS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results

      Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Affirms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the first quarter ended March 31, 2025, in a shareholder letter that is posted at investors.him

      5/5/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025

      Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day. The conference call can be accessed by dialing (888) 510-2630 for U.S. participants and (646) 960-0137 for international participants, referencing conference ID 1704296. A live audio webcast will be available at https://investors.hims.com and will be archived for one year. Upcoming Conference Participation Hims & Hers also announced that members of the company's management team

      4/14/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Revenue of $1.5 billion, up 69% year-over-year in 2024 Net income of $126 million; Adjusted EBITDA of $177 million in 2024 Subscribers grew to 2.2 million, up 45% year-over-year in 2024 Provides Q1 and full year 2025 guidance, with full year 2025 revenue in the range of $2.3 billion to $2.4 billion and Adjusted EBITDA in the range of $270 million to $320 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the fourth quarter and full year ended December 31, 2024 in a shareholder letter that is posted at investors.hims.com. "2024 was a fantastic year at Hims and Hers as we con

      2/24/25 4:05:00 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Operating Officer Baird Melissa exercised 33,333 shares at a strike of $2.43 and sold $1,867,376 worth of shares (33,333 units at $56.02) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:27 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $181,160 worth of shares (3,235 units at $56.00), decreasing direct ownership by 2% to 156,427 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/13/25 5:07:16 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Chief Legal Officer Boughton Soleil sold $97,695 worth of shares (3,236 units at $30.19), decreasing direct ownership by 2% to 159,662 units (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      4/30/25 6:01:31 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Manuel Anja bought $132,260 worth of shares (5,000 units at $26.45) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      11/14/24 4:57:45 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Payne Christopher D bought $1,951,763 worth of shares (110,000 units at $17.74) (SEC Form 4)

      4 - Hims & Hers Health, Inc. (0001773751) (Issuer)

      5/22/24 4:16:26 PM ET
      $HIMS
      Medical/Nursing Services
      Health Care

    $HIMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hims & Hers Health downgraded by TD Cowen with a new price target

      TD Cowen downgraded Hims & Hers Health from Buy to Hold and set a new price target of $30.00

      4/29/25 8:05:51 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Hims & Hers Health from Overweight to Equal-Weight and set a new price target of $60.00 from $42.00 previously

      2/18/25 7:09:28 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care
    • Hims & Hers Health downgraded by Citigroup with a new price target

      Citigroup downgraded Hims & Hers Health from Neutral to Sell and set a new price target of $25.00 from $24.00 previously

      1/10/25 7:53:16 AM ET
      $HIMS
      Medical/Nursing Services
      Health Care